A Survivor Of The GLP-1 Massacre

The GLP-1 stock massacre of 2025 was brutal, indiscriminate, and thoroughly predictable.

Viking Therapeutics (VKTX) got caught in the crossfire, dropping from its peak alongside every other obesity drug hopeful when the market decided a price war was imminent.

I watched the selling cascade through the sector like an avalanche, taking down pre-revenue biotechs and established players alike. Viking’s now trading at $29, the bleeding’s stopped, and something interesting is happening in the accumulation pattern.

The question is whether this consolidation represents smart money positioning for Phase III results or just another dead-cat bounce in a sector that’s lost its narrative.

Novo Nordisk’s (NVO) $200 billion market cap evaporation reminds us that fortunes shift fast in this space. Viking’s a pre-revenue biotech burning $60-90 million per quarter with no approved products and a commercial strategy still being built.

Yet management’s moving forward like approval is inevitable, hiring Neil Aubuchon to lead commercialization and signing manufacturing agreements with CordenPharma for VK2735 production at scale.

This is either confidence or hubris, and in biotech, the difference becomes clear around Phase III data release.

Meanwhile, Viking is positioning itself to move fast if trials succeed, with dual-track optionality- VK2735 subcutaneous in Phase III, oral formulation completing Phase IIa. Both are in maintenance dosing studies, which could provide a legitimate competitive edge.

Eli Lilly (LLY) and Novo require ongoing weekly or monthly injections to maintain weight loss. If Viking demonstrates effective maintenance with less frequent dosing after initial reduction, that’s a real clinical advantage in a market concerned about lifetime costs and patient compliance.

Phase I showed 8% weight loss after four weekly doses with no plateau. The next hurdle is to prove that it works well enough to justify market share against entrenched competitors with massive distribution.

Wall Street projects $1.4 billion in 2030 revenue with $500 million positive free cash flow. Those numbers assume successful Phase III, FDA approval, manufacturing scale-up, commercial launch, and market share capture in an increasingly competitive segment.

The obesity drug market keeps growing through 2030 despite pricing pressure, but the easy money’s been made by Lilly and Novo. Viking’s fighting for differentiation on efficacy, safety, dosing convenience, or cost.

The cash runway question is more interesting than it appears.

Management is guiding for a $60-90 million quarterly burn, about $300 million annually at the midpoint. Analysts are modeling over $600 million in negative free cash flow, which implies either management being conservative or Wall Street’s missing something in their expense assumptions.

The gap matters because it determines how long Viking can stay independent, which determines its leverage in partnership negotiations. A longer cash runway means they can be selective about deals instead of desperate, which typically translates to better economics for shareholders.

The chart tells a useful story. Viking ran to absurd heights during GLP-1 mania, crashed when reality set in, bottomed in April 2025, and has been consolidating in a tight range since. No panic, no capitulation, no FOMO spikes. Just steady, methodical accumulation suggesting institutional buyers are building positions ahead of Phase III readouts.

This pattern typically precedes either a significant move higher on positive data or a grinding decline if trials disappoint.

The go-to-market flexibility that management keeps emphasizing is code for “we’re open to being acquired, but we’ll pretend we can go it alone.”

Viking mentioned all options are on the table – independent commercialization, partnership, or outright sale.

Translation: they’ll take the best offer, but they’re not going to look desperate.

Hiring a commercial leader and signing manufacturing agreements strengthens their negotiating position by demonstrating they have a credible path to independent launch if partnership terms aren’t attractive.

The realistic scenario is that Viking completes Phase III, releases data that’s good enough to validate the mechanism but not spectacular enough to command premium pricing, and either partners with a larger pharma company for commercialization or gets acquired outright.

Takeover premiums in biotech typically run 40% or higher, which would put Viking north of $40 from current levels.

The risk is that Phase III data disappoints, the market share assumptions prove optimistic, or the obesity drug pricing environment deteriorates faster than revenue can ramp.

At $29, Viking’s a speculative position sized accordingly. The technical setup is constructive, the cash runway appears adequate, the pipeline has legitimate optionality with dual formulations, and the maintenance dosing angle could provide real differentiation.

Whether any of that translates to investment returns depends entirely on clinical trial results that won’t be fully known until late 2026 or early 2027.

For those comfortable with binary biotech risk and the attention span to wait through trial readouts, Viking’s interesting.

For everyone else, there are easier ways to play the obesity drug market without wondering if you’re catching a falling knife or accumulating ahead of the next avalanche.